Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Vysis, Inc. (NasdaqNM:VYSI)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | SEC | Msgs | Insider | Financials
Location
3100 Woodcreek Drive
Downers Grove, IL 60515
Phone: (630) 271-7000
Fax: (630) 271-7008
Employees (last reported count): 133
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 73%
·Over the last 6 months:
 · one insider buy; 5,000  shares
 · one insider sell; 12.0K shares
  (0.2% of insider shares)
·Institutional: 81% (295% of float)
(45 institutions)
·Net Inst. Buying: 365.0K shares (+4.23%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Vysis, Inc. is a genomic disease management company that develops, commercializes and markets Deoxyribonucleic Acid (DNA)-based clinical products that provide information critical to the evaluation and management of cancer, prenatal disorders and other genetic diseases. Vysis markets six United States Food and Drug Administration- or foreign-cleared or approved clinical products in addition to distributing over 300 analyte specific reagent and research products through its direct sales operations in the United States and Europe and a worldwide distribution network covering 59 countries. The Company's wholly owned subsidiary, Gene-Trak Systems Industrial Diagnostics Corporation, manufactures and markets food testing kits based on DNA probes. The Company operates in two business segments, genetic testing and food testing products.
More from Market Guide: Expanded Business Description

Financial Summary
Vysis is a genomic disease management company that develops and markets clinical products that provide critical information for the evaluation and management of cancer, prenatal disorders and other genetic diseases. For the six months ended 6/30/01, revenues rose 27% to $13.3 million. Net income from continuing operations totalled $2.1 million, vs. a loss of $2.2 million. Results reflect higher clinical and ASR/Research product sales, and the absence of $1.5 million in clinical data costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Walter Quanstrom, Ph.D., 58
Chairman
--  
John Bishop, 56
Pres, CEO
$268K
John Sluis, 55
CFO, Sr. VP-Fin.
--  
Paul Steuperaert, 61
Pres- European Operations
169K
William Murray, 47
VP, Sec., Gen. Counsel
158K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:VYSIAs of 31-Aug-2001
Price and Volume
52-Week Low
on 19-Oct-2000
$5.219
Recent Price$23.83 
52-Week High
on 26-June-2001
$29.50 
Beta0.51 
Daily Volume (3-month avg)55.9K
Daily Volume (10-day avg)13.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change+172.3%
52-Week Change
relative to S&P500
+265.4%
Share-Related Items
Market Capitalization$244.3M
Shares Outstanding10.3M
Float2.80M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$1.53 
Earnings (ttm)$0.36 
Earnings (mrq)$0.10 
Sales (ttm)$2.29 
Cash (mrq)$1.22 
Valuation Ratios
Price/Book (mrq)15.61 
Price/Earnings (ttm)66.38 
Price/Sales (ttm)10.42 
Income Statements
Sales (ttm)$25.4M
EBITDA (ttm)$3.37M
Income available to common (ttm)$3.99M
Profitability
Profit Margin (ttm)15.7%
Operating Margin (ttm)8.5%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)18.31%
Return on Equity (ttm)29.72%
Financial Strength
Current Ratio (mrq)2.77 
Debt/Equity (mrq)0 
Total Cash (mrq)$12.4M
Short Interest
As of 8-Aug-2001
Shares Short69.0K
Percent of Float2.5%
Shares Short
(Prior Month)
48.0K
Short Ratio2.16 
Daily Volume32.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.